Background
==========

Glucose metabolism disorders are common in extremely low birth weight (ELBW) infants and are associated with high morbidity and mortality \[[@B1]-[@B9]\]. This study was conducted to evaluate the prevalence and risk factors associated with both hypo and hyperglycemia in ELBW infants.

Materials and methods
=====================

All inborn ELBW neonates admitted to our NICU during a 5-year period were eligible for this retrospective analysis. Exclusion criteria were: birth weight (BW) \<400 grams, major congenital malformations, death during the first 24 hours of life. Hypoglycemia was defined as blood glucose level (BGL) ≤45 mg/dL; hyperglycemia as BGL\>240 mg/dL in a single determination or \>180 mg/dL in two determinations at 2-hour intervals. Continuous intravenous insulin infusion was started after an ineffective glucose restriction.

Results
=======

Of 195 ELBW infants, 29 (14.8%) were excluded and 166 (GA 26.7 2.1 weeks, BW 751 152 grams) were analyzed and grouped to their BGL. Normoglycemia was observed in 79 neonates (47.6%) (N-Group); 80 neonates (52.4%) showed abnormal BGL: 21 (12.7%) were hypoglycemic (Hypo-Group), 53 (31.9%) hyperglycemic (Hyper-Group) and 13 (7.8%) showed both hypoglycemia and hyperglycemia (Hypo&Hyper-Group). Clinical characteristics of the groups are reported in Table [1](#T1){ref-type="table"}. Hypo-Group respect to N-Group showed a higher rate of small for gestational age (SGA) neonates (p=0.03). Hyper-Group in comparison to N-Group showed a tendency toward a lower GA (p=0.05), lower BW (p\<0.001), higher sepsis rate (p\<0.001), higher rate of treatment with inotropic agents (p=0.02), corticosteroids (p=0.006) and nonsteroidal antiinflammatory drugs (p=0.01). Hypo&Hyper-Group respect to N-Group showed similar GA, lower BW (p\<0.001), higher sepsis rate (p\<0.01), higher rate of inotropic treatment (p=0.04). Insulin was administered in 35 neonates (66%) of Hyper-Group and in 8 neonates (61.5%) of Hypo&Hyper-Group. Intraventricular Hemorrhage**(** IVH) rate was higher in Hyper-Group and Hypo&Hyper-Group respect to N-Group (p=0.002) as well as IVH grade3 (p=0.001 and p=0.02, respectively).The rate of both Retinopathy of Prematurity**(** ROP) and ROP ≥stage 2 in survived neonates was higher in Hyper-Group respect to N-Group (p=0.008 and p=0.002, respectively). Mortality was similar among the groups (Table [2](#T2){ref-type="table"}).

###### 

Demographic data and risk factors in the study groups

                                     N-Group N=79   Hypo-Group N=21   Hyper-Group N=53   Hypo&Hyper-Group N=13
  ---------------------------------- -------------- ----------------- ------------------ -----------------------
  GA (wks), *mean±SD*                26.8±2.0       27.7±2.4          26.1±2.1           26.8±1.8
  BW (g), *mean±SD*                  808±136        719±140           695±146            692±140
  Male, n (%)                        17 (21.5)      10 (47.6)         26 (49.0)          8 (61.5)
  SGA, n (%)                         22 (27.8)      11 (52.3)         16 (30.1)          4 (30.7)
  Apgar^1^ \<6, n (%)                39 (49.3)      9 (42.8)          34 (64.1)          8 (61.5)
  Apgar^5^ \<6, n (%)                8 (10.1)       0                 9 (16.9)           2 (15.3)
  Intubation, n (%)                  47 (59.4)      11 (52.3)         37 (69.8)          10 (76.9)
  Antenatal Steroid, n (%)           64 (81.0)      17 (80.9)         41 (77.3)          12 (92.3)
  RDS, n (%)                         66 (83.5)      19 (90.4)         49 (92.4)          13 (100)
  Sepsis, n (%)                      16 (20.2)      4 (19.0)          32 (60.3)          7 (53.8)
  Inotropic Agents, n (%)            26 (32.9)      6 (28.5)          28 (52.8)          8 (61.5)
  Xanthines, n (%)                   70 (88.6)      20 (95.2)         50 (94.3)          13 (100)
  Postnatal Steroid, n (%)           11 (13.9)      3 (14.2)          18 (33.9)          3 (23.0)
  NEC, n (%)                         6 (7.5)        2 (9.5)           5 (9.4)            4 (30.7)
  Medical treatment for PDA, n (%)   34 (43.0)      8 (38.0)          34 (64.1)          9 (69.2)
  Surgical Procedures, n (%)         5 (6.3)        3 (14.2)          7 (13.2)           2 (3.7)

RDS: Respiratory Distress Syndrome; PDA: Patent Ductus Arteriosus; NEC: Necrotizing enterocolitis

###### 

Complications and outcome in the study groups

                                           N-Group N=79      Hypo-Group N=21   Hyper-Group N=53   Hypo&Hyper-Group N=13
  ---------------------------------------- ----------------- ----------------- ------------------ -----------------------
  IVH, n (%)                               17 (21.5)         7 (33.3)          25 (47.1)          8 (61.5)
  IVH (grade 3, n (%)                      5 (6.3)           1 (4.7)           15 (28.3)          4 (30.7)
  ROP all stages in the survivors, n (%)   49 of 61 (80.3)   10 of 16 (62.5)   35 of 35 (100)     7 of 8 (87.5)
  ROP \> stage 2 in the survivors, n (%)   35 of 71 (57.3)   9 of 16 (56.2)    35 of 35 (100)     6 of 8 (75)
  Mortality, n (%)                         18 (22.7)         5 (23.8)          18 (33.9)          6 (46.1)

IVH: IntraventricularHemorrhage; ROP: Retinopathy of Prematurity

Conclusions
===========

Among ELBW infants, hypoglycemia occurs more frequently in SGA neonates, while hyperglycemia alone or a marked variability of BGL (hypo and hyperglycaemia) is more common in sick neonates. High rate of glucose homeostasis disorders highlights the importance of carefully monitoring BGL in order to a prompt management. Continuous glucose monitoring recently used in neonates \[[@B10]\] might be a useful tool for monitoring glucose changes also in ELBW neonates.
